Company Overview
Ekso Bionics Holdings, Inc. is dedicated to the design, development, distribution, and commercialization of exoskeleton products across the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. Operating within the Healthcare sector, specifically the Medical Instruments & Supplies industry, the company focuses on providing advanced wearable robotic technology such as the EksoNR wearable robotic exoskeleton, the Ekso Indego Therapy powered exoskeleton, and the Ekso I device. The company maintains a market capitalization of $36.17M with an annual revenue of $12.80M and employs a workforce of 50 individuals. These financial figures indicate that Ekso Bionics operates as a micro-cap entity with a very small revenue base relative to its valuation, suggesting a business model that relies heavily on high-margin sales or significant asset-light operations rather than massive volume production. The current scale, characterized by a market cap that is roughly three times its trailing twelve-month revenue, reflects the speculative nature often associated with companies in the medical device sector that are still in growth or commercialization phases.
Financial Health
The company reported a revenue of $12.80M for the trailing twelve months, yet it posted a net income of $-11,921,000 and an EBITDA of $-11,003,000. The substantial gap between the $12.80M revenue and the $-11,921,000 net income reveals a highly leveraged cost structure where operating expenses and costs of goods sold significantly exceed total sales, resulting in a loss exceeding the total revenue generated. Free cash flow stands at $-4,496,125, which indicates that the company is consuming its liquid assets to fund operations and potentially capital expenditures, thereby limiting its current financial flexibility and ability to weather economic downturns without raising additional capital. The gross margin is reported at 53.5%, suggesting that the core product pricing is strong relative to the cost of goods sold, while the operating margin of -119.7% and profit margin of -91.4% demonstrate that general and administrative expenses, or research and development costs, are consuming a disproportionate amount of the company's top-line revenue. On the balance sheet, the company holds $1.17M in cash against $4.64M in debt, resulting in a debt-to-equity ratio of 51.45, which classifies the entity as highly leveraged with a liability structure that exceeds its equity base. The current ratio is 1.63, indicating that the company possesses sufficient current assets to cover its current liabilities, providing a moderate buffer for short-term liquidity despite the ongoing operational losses. Furthermore, the return on equity is -107.6% and the return on assets is -33.6%, metrics that reveal that management has not yet been effective at generating positive returns on the capital invested in the business, a common challenge for pre-profitability medical device firms.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is listed at -53.42, a figure that implies the market is pricing in a continued expectation of negative earnings or is utilizing a non-standard metric for companies currently unprofitable. The price-to-book ratio stands at 4.00, which indicates that the market is valuing the company at four times its book value, suggesting a significant premium over the net asset value that investors are attributing to future growth potential or intangible assets not fully captured on the balance sheet. Additionally, the price-to-sales ratio is 2.83 and the EV/EBITDA is -3.60, providing alternative perspectives that suggest the stock is trading at a premium relative to its sales volume but at a negative multiple of earnings, highlighting the difficulty in traditional valuation for loss-making biotech or medtech firms. The 52-week high is $13.50 and the 52-week low is $2.73, meaning the current price sits at a position that reflects significant volatility and a wide trading range within the past year. The beta value is 0.84, which indicates that the stock price volatility is slightly lower than the broader market, suggesting that Ekso Bionics moves with a moderate degree of sensitivity to overall market swings rather than acting as a highly defensive or highly aggressive play.
Growth & Income
The revenue growth year-over-year is -38.3%, while earnings growth is N/A due to the company's unprofitable status. The decline in revenue suggests a contraction in sales or a reduction in the number of units sold compared to the prior year, which is a critical concern for a company with such high operating expenses. Since the company does not pay a dividend, as evidenced by the 0.0% payout ratio and N/A dividend yield, it does not distribute cash to shareholders, implying that any retained earnings are instead consumed by operations or reinvested into product development, though the current negative free cash flow limits the scope of such reinvestment. The overall growth and income profile is characterized by negative revenue momentum and a complete absence of income generation or dividend distribution, presenting a challenging environment for investors seeking capital appreciation through earnings expansion or yield.